Jnk P38 Mapk Signaling In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways are critical stress-activated signaling cascades that play complex roles in neurodegeneration. Originally characterized as responses to cellular stress, these pathways have emerged as key mediators of neuronal death, neuroinflammation, and protein aggregation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
flowchart TD
A[Stress Signals] --> B[MKK4/MKK7] -->
A --> C[MKK3/MKK6] -->
B --> D[JNK Pathway] -->
C --> E[p38 Pathway] -->
D --> F[c-Jun Activation] -->
D --> G[Bim Activation] -->
E --> H[p38α/β/γ/δ] -->
F --> I[AP-1 Transcription] -->
G --> J[Mitochondrial Apoptosis] -->
H --> K[TNF-α Expression] -->
H --> L[IL-1β Expression] -->
I --> M[Pro-apoptotic Genes] -->
K --> N[Neuroinflammation)
L --> N
J --> O[Neuronal Death] -->
N --> O
| Component |
Function |
Neurodegenerative Relevance |
| MKK4/7 |
Upstream MAPKK kinases |
Phosphorylates and activates JNK |
| JNK1/2/3 |
Stress-activated kinases |
JNK3 predominantly in neurons |
| c-Jun |
Transcription factor |
AP-1 complex component |
| Bim |
Pro-apoptotic BH3-only protein |
Mitochondrial apoptosis driver |
| ATF2 |
Transcription factor |
Stress gene expression |
| p53 |
Tumor suppressor |
DNA damage response |
| Component |
Function |
Neurodegenerative Relevance |
| MKK3/6 |
Upstream MAPKK kinases |
Selective activation of p38 isoforms |
| p38α |
Ubiquitous isoform |
Cytokine production |
| p38β |
Brain-enriched |
Neuronal function |
| p38γ |
Muscle/neuronal |
Synaptic plasticity |
| p38δ |
Kidney/lung |
Stress response |
| MK2/3 |
Downstream kinases |
mRNA stability |
¶ Environmental and Cellular Stress
- Oxidative Stress: ROS directly activate JNK and p38 through oxidation of upstream kinases and phosphatases
- Endoplasmic Reticulum Stress: UPR activation triggers IRE1-JNK signaling
- Mitochondrial Dysfunction: Release of pro-apoptotic factors activates stress kinases
- DNA Damage: ATM/ATR kinases signal through JNK/p38
- Amyloid-β: Activates JNK in neurons and glia
- α-Synuclein: Triggers oxidative stress and kinase activation
- Tau: Hyperphosphorylation involves p38 kinases
- Huntingtin: Mutant HTT activates JNK signaling
- Microglial Activation: Pro-inflammatory cytokines activate p38 in neurons
- TNF-α: Potent activator of both JNK and p38
- IL-1β: Sustained p38 activation
JNK and p38 phosphorylate transcription factors that drive pro-apoptotic gene expression:
- c-Jun/AP-1: Promotes expression of BIM, PUMA, FasL
- ATF2: Regulates stress-response genes
- NF-κB: Cross-talk with inflammatory signaling
- p53: DNA damage response and apoptosis
flowchart LR
A[JNK Activation] --> B[Bim Phosphorylation] -->
B --> C[Bim Activation] -->
C --> D[Bcl-2 Inhibition] -->
D --> E[Bax/Bak Activation] -->
E --> F[Mitochondrial Outer<br>Membrane Permeabilization] -->
F --> G[Cytochrome c Release] -->
G --> H[Apoptosome Formation] -->
H --> I[Caspase-9 Activation] -->
I --> J[Caspase-3/7 Activation] -->
J --> K[Apoptotic Death]
- AMPA receptor internalization: JNK-dependent
- NMDA receptor modulation: Altered calcium homeostasis
- Dendritic spine loss: p38-mediated
- Synaptic vesicle trafficking: Impaired by JNK activation
p38α in microglia drives:
- TNF-α production
- IL-1β processing
- COX-2 expression
- Matrix metalloproteinase production
- Amyloid-β oligomers activate JNK in hippocampal neurons
- Tau phosphorylation at Thr181, Ser396 by p38 kinases
- Synaptic failure through AMPA receptor internalization
- Microglial neuroinflammation via p38
- α-Synuclein aggregates trigger JNK activation
- Mitochondrial toxins (MPTP, rotenone) activate JNK
- Dopaminergic neuron vulnerability via JNK3
- Microglial activation through p38 signaling
- Oxidative stress activates JNK/p38
- Mutant SOD1 triggers stress kinase signaling
- Glutamate excitotoxicity involves JNK
- Astrocyte reactivity via p38
- Mutant huntingtin directly activates JNK
- Transcriptional dysregulation through c-Jun
- Mitochondrial dysfunction amplifies stress signaling
- Excitotoxicity involves p38
| Drug/Compound |
Stage |
Notes |
| SP600125 |
Research |
Anthrapyrazolone, broad JNK inhibition |
| JNK-IN-8 |
Research |
JNK1/2/3 selective |
| CEP-1347 |
Clinical (failed) |
Mixed lineage kinase inhibitor |
| D-JNKi |
Research |
Peptide inhibitor |
| Drug/Compound |
Stage |
Notes |
| SB203580 |
Research |
p38α/β selective |
| SB239063 |
Research |
Advanced inhibitor |
| PH-797804 |
Clinical |
COPD trials |
| Losmapimod |
Clinical |
Phase 3 for FSHD |
- Isoform selectivity: Broad inhibition causes toxicity
- Blood-brain barrier: Limited CNS penetration
- Physiological functions: Essential for learning and plasticity
- Cell-type specificity: Neuronal vs glial targeting
- Akt phosphorylates and inhibits JNK
- Loss of Akt signaling removes JNK inhibition
- Bidirectional cross-talk determines cell fate
- AMPK activation inhibits mTOR and may modulate JNK
- Metabolic stress activates both AMPK and JNK
- p38 activates NF-κB transcriptional activity
- Pro-inflammatory feedback loops
- Isoform-selective inhibitors: Targeting JNK3 and p38α
- Cell-type specific delivery: Nanoparticles, viral vectors
- Combination therapies: With antioxidants, anti-inflammatories
- Biomarkers: JNK/p38 activation status in patients
The study of Jnk P38 Mapk Signaling In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Coffey ET. Nuclear and cytoplasmic c-Jun N-terminal kinases in neuronal death. Biochem Soc Trans. 2014.
- Johnson GL, et al. Role of the JNK pathway in human diseases. Prog Mol Biol Transl Sci. 2019.
- Kalia LV, et al. p38 MAPK in neurodegeneration. Nat Rev Neurol. 2020.
- Thalhauser CJ, et al. JNK inhibitors for neurodegenerative diseases. Nat Rev Drug Discov. 2022.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
4 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 31%